Mylan sees 2Q revenue grow 8 percent
Mylan NV Tuesday reported its second quarter revenue rose 8 percent to $2.56 billion.
The generic pharmaceutical giant, which is incorporated in the Netherlands but runs its operations from Southpointe, had adjusted earnings per share of $1.16, topping analysts’ estimates of $1.13.
While the company’s revenue missed analysts’ estimates of $2.57 billion, Mylan CEO Heather Bresch said the company is maintaining its full-year earnings outlook of between $4.85 and $5.15 per share.
“This solid performance, which included continued strength in our generics business and double-digit revenue growth in our specialty business, yet again underscores the strategic value of Mylan’s diversification and scale as well as our differentiation within our industry,” Bresch said in a statement.